联合治疗:改善慢性肾脏病肾脏与心血管结局的新范式
本文综述了伴糖尿病慢性肾脏病(CKD)联合治疗的最新进展。全球CKD负担自1990年代几乎翻倍,主要由糖尿病驱动,CKD、糖尿病、肥胖与心血管病共同构成心血管-肾脏-代谢(CKM)综合征。SGLT2抑制剂、GLP-1受体激动剂和非甾体盐皮质激素受体拮抗剂非奈利酮通过互补机制降低代谢、肾脏与心血管风险,现有证据支持联合使用,并可减少高钾血症等副作用。
要点
- SGLT2抑制剂、GLP-1RA与非奈利酮机制互补,联合治疗可产生叠加保护效应。
- SGLT2抑制剂联合非奈利酮有助于降低高钾血症风险。
- 联合治疗可依据患者个体特征定制,多项CKM综合征试验正在进行中。
核心结论
- 现有临床前与临床证据支持在CKD中采用联合治疗,通过代谢、血流动力学及促炎促纤维化通路实现叠加甚至协同的心肾保护。
研究设计与样本
- 本文为叙述性综述,回顾伴糖尿病CKD联合治疗证据并讨论正在与未来开展的联合治疗试验。
主要发现
- 全球CKD负担在1990至2016年间增加近90%,主要归因于糖尿病中CKD患病率增加。
- CKD患者终生心血管疾病风险高于一般人群,且风险随白蛋白尿和肾功能下降而平行增加。
- SGLT2抑制剂、GLP-1RA与非奈利酮已迅速成为指南导向药物治疗(GDMT)的基石。
- 近期完成的醛固酮合酶抑制剂和内皮素受体拮抗剂试验报告,在肾素-血管紧张素系统与SGLT2抑制背景上具有叠加降蛋白尿效应且安全性可接受。
关键数值与推荐
- SGLT2抑制剂、GLP-1RA与非奈利酮通过互补作用机制降低代谢、肾脏和心血管风险。
- SGLT2抑制剂与非奈利酮联用有助于降低高钾血症风险。
临床怎么用
- 在伴糖尿病CKD患者中,应考虑联合使用SGLT2抑制剂、GLP-1RA与非奈利酮等指南导向药物以改善心肾结局。
- 联合治疗可根据患者个体特征和需求进行定制,并需建立流程将新疗法纳入日常实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: In this article the authors review recent advances in the treatment of chronic kidney disease (CKD) with diabetes, and summarize evidence supporting combination therapy approaches to improve patient outcomes. Driven by the global rise in diabetes, the worldwide burden of CKD has nearly doubled since the 1990s. People with CKD have notably increased risks for premature cardiovascular disease (heart and blood vessels disease), kidney failure and death. CKD, diabetes, obesity and cardiovascular disease are closely interrelated and share common risk factors. These health conditions therefore comprise what is now known as cardiovascular-kidney-metabolic (CKM) syndrome. Recently approved medications, including sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and the non-steroidal mineralocorticoid receptor antagonist (ns-MRA) finerenone, represent agents capable of reducing metabolic, kidney and cardiovascular risk through complementary mechanisms of action. Current evidence supports use of these therapies in combination. Besides providing additive protective effects, combination therapy may also help reduce side effects. For instance, using an SGLT2 inhibitor in combination with finerenone helps decrease the risk for high potassium levels. Through the multipronged approach, combination therapy allows tailoring treatment for the individual patient characteristics and needs. Several planned and ongoing clinical trials continue to study the benefits of combination therapy in people with CKM syndrome. With building evidence supporting the use of combination therapy, it is crucial to raise awareness of the importance of this treatment approach and develop processes to incorporate new therapies into every day practice to support optimal care and improved outcomes. ABSTRACT: The global burden of chronic kidney disease (CKD) increased by nearly 90% in the period spanning 1990 to 2016, mostly attributed to an increase in the prevalence of CKD in diabetes. People living with CKD have an elevated lifetime risk for cardiovascular disease (CVD) when compared with the general population, with risk increasing in parallel with albuminuria and kidney function decline. Metabolic disease, CKD and CVD share common risk factors including neurohumoral activation, systemic inflammation and oxidative stress, thus prompting the introduction of a broader construct of cardiovascular-kidney-metabolic (CKM) syndrome. An important rationale for the introduction of this concept are recent and ongoing therapeutic advancements fundamentally changing CKM management. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and the non-steroidal mineralocorticoid receptor antagonist (ns-MRA) finerenone have shifted the therapeutic paradigm for patients with CKD and have emerged in rapid succession as cornerstones of guideline-directed medical therapy (GDMT). Recently completed clinical trials of aldosterone synthase inhibitors and endothelin receptor antagonists have additionally reported additive antiproteinuric effects on the background of renin-angiotensin system and SGLT2 inhibition, with acceptable safety profiles. The sum of current evidence from both preclinical and clinical studies support combination therapy in the setting of CKD to achieve additive and potentially synergistic kidney and heart protection by addressing metabolic, hemodynamic, and pro-inflammatory and pro-fibrotic mechanistic pathways. This narrative review will discuss available evidence supporting combination GDMT in CKD with diabetes and additionally discuss ongoing and future trials evaluating the efficacy and safety of combination therapies for CKD with or without diabetes.
引用
- Alicic RZ, Neumiller JJ, Tuttle KR, et al. Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease. Nephrol Dial Transplant. 2025. PMID: 39907543. doi:10.1093/ndt/gfae212
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。